Differential Neutralization Profiles of 17DD Vaccinated Population to 17D-204 and 17DD Vaccine Strains
- PMID: 39771973
- PMCID: PMC11679407
- DOI: 10.3390/vaccines12121311
Differential Neutralization Profiles of 17DD Vaccinated Population to 17D-204 and 17DD Vaccine Strains
Abstract
Background/Objectives: Yellow fever virus (YFV) (Flaviviridae, Orthoflavivirus) is the etiologic agent of yellow fever (YF), a vector-borne disease with significant morbidity and mortality across the tropics and neotropics, despite having a highly efficacious and safe vaccine (17D). Vaccination provides lifelong protection from YF disease mediated by humoral immunity. There are several versions of the original 17D vaccine: 17D-204 (marketed in the USA as YF-VAX, in France as Stamaril, and in China as Tiantan-V), 17D-213 (Russian Federation), and 17DD (by FIOCRUZ in Brazil). Vaccines produced in the US, France, Senegal, China, and Russia represent 17D-204-derived strains, whereas the Brazilian 17DD has a unique passage/attenuation history from 17D-204-derived strains. Their functional differences in the neutralization profiles are not known. Methods: The Plaque Reduction Neutralization Test (PRNT) was used to determine the neutralization profiles of sera from 209 patients that were previously vaccinated with the 17DD strain against both 17D-204 and 17DD. Results: Sera exhibited significantly more efficient neutralization of 17DD (mean reciprocal PRNT50 183, PRNT80 86, median reciprocal PRNT50 80, and PRNT80 40) compared to 17D-204 (mean reciprocal PRNT50 91, PRNT80 33, median reciprocal PRNT50 40, and PRNT80 10). Conclusions: Our data indicate antigenic differences between 17D and 17DD vaccines.
Keywords: YFV; immune response; neutralizing antibodies; vaccine.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures

Similar articles
-
17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.PLoS One. 2012;7(12):e49828. doi: 10.1371/journal.pone.0049828. Epub 2012 Dec 10. PLoS One. 2012. PMID: 23251351 Free PMC article. Clinical Trial.
-
Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.Microbiol Spectr. 2024 May 2;12(5):e0370323. doi: 10.1128/spectrum.03703-23. Epub 2024 Mar 21. Microbiol Spectr. 2024. PMID: 38511952 Free PMC article.
-
Ontogeny of yellow fever 17D vaccine: RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced world-wide.J Gen Virol. 1983 Mar;64 Pt 3:627-37. doi: 10.1099/0022-1317-64-3-627. J Gen Virol. 1983. PMID: 6298349
-
The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences.Expert Rev Vaccines. 2018 Jan;17(1):79-90. doi: 10.1080/14760584.2018.1406800. Epub 2017 Nov 27. Expert Rev Vaccines. 2018. PMID: 29172832 Review.
-
T Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal Models.Viruses. 2017 Apr 11;9(4):77. doi: 10.3390/v9040077. Viruses. 2017. PMID: 28398253 Free PMC article. Review.
References
-
- ICTV . Virus Taxonomy: 2023 Release (MSL #39) ICTV; Jena, Germany: 2023. [(accessed on 24 September 2024)]. Available online: https://ictv.global/taxonomy.
-
- Pierson T.C., Diamond M.S. Flaviviruses. In: Knipe D.M., Howley P.M., editors. Fields Virology. 6th ed. Volume 1. Wolters Kluwer Health Adis (ESP); Philadelphia, PA, USA: 2013. p. 2664.
Grants and funding
LinkOut - more resources
Full Text Sources